How is Cyrus different from other modeling software?
For over a half century, molecular modeling methods have been applied to small molecule discovery, with many notable successes. Focus is now increasingly being directed to proteins as therapeutics or synthetic biology tools, and to computational methods that can be applied to the structure prediction and design of these valuable proteins. Much of this protein comparative modeling and design work has been based solely on predictive approaches derived from first principle physics.
Rosetta, available commercially as Cyrus Bench, has fundamentally changed protein structure prediction and protein design through the use of a scoring function that reflects a combination of key physical insights from traditional methods and statistical knowledge from the vast accumulation of protein structures solved over the last six decades. This combined approach is very different from all other commercially-available software toolkits such as Schrodinger, CCG MOE, and BIOVIA Discovery Studio, and has leapfrogged other methods for protein modeling.
Since 2009-2010 Rosetta has been responsible for a variety of key advances in computational protein design and engineering, with a major focus in the design of novel protein/protein interactions. This includes the design of the first high affinity protein/protein binding interaction, and the first designed “de novo” proteins with high affinity to a molecular target not derived from natural protein sequences. These accomplishments are unique to Rosetta in the peer-reviewed literature, and have not been repeated by tools in Schrodinger’s BioLuminate, CCG MOE or BIOVIA Discovery Studio. You can read more below about these critical scientific advantages of Cyrus Bench.
These Rosetta tools are now accessible through Cyrus Bench, and are helping Cyrus customers advance their discovery programs into pre-clinical and clinical trials. These tools in Cyrus Bench also offer a more powerful alternative for computational protein engineering than protein viewing tools such as pymol or chimera which offer imaging capabilities but not protein modeling and engineering methods.
Our mission is to transform therapeutics and synthetic biology discovery, accelerating new treatments and protein-based materials to market, and creating entirely new treatments computationally that are difficult or impossible to identify using conventional means.
Click to Learn More